Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-targeting dexabody
- Development stage
- Preclinical
- Lead developer
- Dextera Biosciences
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous, Subcutaneous
01
Overview
HER2-targeting dexabody is a preclinical-stage therapeutic candidate being developed by Dextera Biosciences for the treatment of HER2-positive cancers. The drug utilizes Dextera's proprietary 'dexabody' platform, which consists of synthetic D-proteins—mirror-image versions of natural L-proteins. These D-proteins are engineered to be highly stable, resistant to proteolytic degradation, and potentially non-immunogenic due to their non-natural stereochemistry. This specific asset is a payload conjugate, functioning as a peptide-drug conjugate (PDC) where the HER2-targeting D-protein serves as a delivery vehicle for a cytotoxic payload, aiming to provide targeted destruction of tumor cells while minimizing off-target effects.
- Other names
- HER2-targeting dexabodyHER-2-targeting dexabodyHER 2-targeting dexabody
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-targeting dexabody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-targeting dexabody.